Several factors, including diminishing financial return, and the lack of new discovery platforms and others, have had a cooling effect on pharmaceutical companies\' activity in the area of antibacterial drug
Several factors, including diminishing financial return, and the lack of new discovery platforms and others, have had a cooling effect on pharmaceutical companies\’ activity in the area of antibacterial drug development. At the same time, we are witnessing the wide spread of resistant bacteria, leading to untreatable infections. \’We are facing a huge crisis worldwide not having an antibiotics pipeline,\’ said Dr. Janet Woodcock, the Director of CDER at FDA, in her recent interview for NYT. The governments of European countries and the United States have created several incentives for the industry to rise to the challenge, therefore, many companies are exploring the opportunities to start or re-open their antibacterial departments, or to stimulate the existing research and development. Cambridge Healthtech Institute is pleased to present its inaugural “Re-Entering Antibacterial Drug Development Summit” that includes a science track, a business track, and features a wide range of pivotal issues. This Summit is designed as a forum for knowledge and opinion exchange between the major stakeholders, shaping the current state of antibacterial discovery and development.
New discovery platforms, novel screens, and approaches are needed to develop new antibacterials, and to stop the dangerous trends of multidrug microbial resistance. The “Targeting the Key Antibacterial R&D Challenges” conference, part of the “Re-Entering Antibacterial Drug Development Summit”, is designed to serve as a scientific hub for researchers in the industry and academia working on new antibiotics. The following topics are going to be discussed: gram negatives, pathogen-specific drug development, antibacterial biologics, mechanisms of resistance, clinical microbiology, and others. Top industry and academia researcher are on the faculty of the meeting.
David C. Hooper, M.D., Professor of Medicine, Harvard Medical School; Chief, Infection Control Unit, Associate Chief, Division of Infectious Diseases, Massachusetts General Hospital
Barry Eisenstein, M.D., Senior Vice President, Scientific Affairs, Cubist Pharmaceuticals Editor, Antimicrobial Agents and Chemotherapy
TOPICS TO BE COVERED:
- Gram Negatives at The Top Of The Unmet Needs List
- Antibacterial Biologics
- The Bacterial Resistance Portfolio
- Sterilizing Antibiotics
- Technology To Serve Antibacterial R&D
october 27 (Monday) - 29 (Wednesday)
Merck Research Building
33 Avenue Louis Pasteur Boston MA